DHAP (chemotherapy)

DHAP in context of chemotherapy is an acronym for chemotherapy regimen that is used for remission induction in cases of relapsed or refractory Non-Hodgkin lymphoma and Hodgkin disease.[1] It is usually given for 2-3 courses, then followed by high-dose chemotherapy and autologous stem cell transplant. In combination with anti-CD20 monoclonal antibody Rituximab (Rituxan, Mabthera) it is called R-DHAP or DHAP-R.

[R]-DHAP regimen consists of:

  1. Rituximab, a monoclonal antibody, directed at B-cell surface antigen CD20
  2. (D)examethasone, a glucocorticoid hormone
  3. (H)igh-dose (A)ra-C - cytarabine, an antimetabolite;
  4. (P)latinol (cisplatin), a platinum-based antineoplastic agent with an alkylating mechanism;

Dosing regimen

Drug Dose Mode Days
(R)ituximab 375 mg/m2 IV infusion Day 0
(D)examethasone 40 mg PO qd Days 1-4
(H)igh-dose Ara-C - cytarabine 2000 mg/m2 IV infusion over 2 hrs Day 2, every 12 hours
(P)latinol (cisplatin) 100 mg/m2 IV infusion over 24 hrs Day 1

References

  1. ↑ Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)
This article is issued from Wikipedia - version of the 3/7/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.